We suggest that inhibitors of the GTωA pathway, which will interfere with closure of the last step of the methionine salvage pathway, may exhibit synergistic or added efficacy with other anti-glutaminase pathway drugs against prostate cancer and other cancers. The gene discussed is GLS; the disease is prostate cancer.